Established and emerging GABAA receptor pharmacotherapy for epilepsy

Robert J Richardson; Steven Petrou; Alexander Bryson

doi:10.3389/fphar.2024.1341472

Established and emerging GABA_A receptor pharmacotherapy for epilepsy

Front Pharmacol. 2024 Feb 21:15:1341472. doi: 10.3389/fphar.2024.1341472. eCollection 2024.

Authors

Robert J Richardson^{1

2}, Steven Petrou^{1

3}, Alexander Bryson^{1

2

4}

Affiliations

¹ Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia.
² Department of Neurology, Austin Health, Heidelberg, VIC, Australia.
³ Praxis Precision Medicines, Boston, MA, United States.
⁴ Department of Neurology, Eastern Health, Melbourne, VIC, Australia.

Abstract

Drugs that modulate the GABA_A receptor are widely used in clinical practice for both the long-term management of epilepsy and emergency seizure control. In addition to older medications that have well-defined roles for the treatment of epilepsy, recent discoveries into the structure and function of the GABA_A receptor have led to the development of newer compounds designed to maximise therapeutic benefit whilst minimising adverse effects, and whose position within the epilepsy pharmacologic armamentarium is still emerging. Drugs that modulate the GABA_A receptor will remain a cornerstone of epilepsy management for the foreseeable future and, in this article, we provide an overview of the mechanisms and clinical efficacy of both established and emerging pharmacotherapies.

Keywords: GABA A receptor; GABA allosteric modulators a; antisense; benzodiazepines; epilepsy; neurosteriod; oligonucleotide-drug conjugates.

Publication types

Review

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.